InFlectis BioScience Overview
- Founded
-
2013
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$36.5M
- Investors
-
7
InFlectis BioScience General Information
Description
Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclinical-stage development products that modulate key proteins involved in misfolded protein disorders areas through early proof-of-concept, enabling clients to maximize the commercial value of each of its products, improve patient care, and generate significant financial returns for shareholders.
Contact Information
Website
www.inflectisbioscience.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 21 rue La Noue Bras de Fer
- 44200 Nantes
- France
+33 02 00 00 00 00
InFlectis BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 04-Jan-2021 | $36.5M | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC (Series A) | 27-May-2016 | 00.00 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Seed Round | 13-Jan-2015 | $2.11M | $2.11M | Completed | Pre-Clinical Trials | |
| 1. Grant | 01-Jan-2014 | $411K | Completed | Pre-Clinical Trials |
InFlectis BioScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference P3 | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| Preference P2 | 0,000 | 00.000000 | ||||||
| Preference P1 | 40,622 | $1.132676 | ||||||
| Class O | 99,549 | $1.132676 |
InFlectis BioScience Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclini
Drug Discovery
Nantes, France
10
As of 2022
000.00
0000000000 0
000.00
000000
s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000 000000000
Lyon, France
000
As of 0000
00000
00000000
00000
000000
nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000 000000000
Burlingame, CA
00
As of 0000
00000
000000 - 000
00000
Add Comparison
InFlectis BioScience Competitors (70)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Erytech Pharma | Formerly VC-backed | Lyon, France | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Bedford, MA | 000 | 00000 | 000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
InFlectis BioScience Patents
InFlectis BioScience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016304331-A1 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. | Active | 31-Jul-2015 | 0000000000 | |
| AU-2016304331-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. | Active | 31-Jul-2015 | 0000000000 | |
| CA-2992674-A1 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | Pending | 31-Jul-2015 | 0000000000 | |
| EP-3328369-A1 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | Pending | 31-Jul-2015 | 0000000000 | |
| US-20180221310-A1 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | Active | 31-Jul-2015 | A61K31/155 |
InFlectis BioScience Executive Team (5)
InFlectis BioScience Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jérôme Guéret | GO Capital (France) | Board Member | 000 0000 |
| Mark Pykett Ph.D | Self | Board Member | 000 0000 |
| Philippe Guedat Ph.D | InFlectis BioScience | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
| Pierre Miniou Ph.D | InFlectis BioScience | Co-Founder, Chief Operating Officer & Board Member | 000 0000 |
| Taro Inaba | Remiges Ventures | Board Member | 000 0000 |
InFlectis BioScience Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
InFlectis BioScience Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Crédit Mutuel Innovation | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Crédit Mutuel Equity | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Remiges Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 | |
| GO Capital (France) | Venture Capital | Minority | 000 0000 | 000000 0 |